Rabenosyn 5 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-88119
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the N-terminal region of Human Rabenosyn 5. Peptide sequence: REGDDRAESGTQGYESFSYGGVDPYMWEPQELGAVRSHLSDFKKHRAARI The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Scientific Data Images for Rabenosyn 5 Antibody
![Western Blot: Rabenosyn 5 Antibody [NBP2-88119]](https://resources.bio-techne.com/images/products/Rabenosyn-5-Antibody-Western-Blot-NBP2-88119-img0001.jpg "Western Blot: Rabenosyn 5 Antibody [NBP2-88119]")
Western Blot: Rabenosyn 5 Antibody [NBP2-88119]
Western Blot: Rabenosyn 5 Antibody [NBP2-88119] - Host: Rabbit. Target Name: RBNS5. Sample Type: 293T Whole Cell lysates. Antibody Dilution: 1.0ug/mlApplications for Rabenosyn 5 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Rabenosyn 5
Alternate Names
110 kDa protein, FLJ34993, FYVE finger-containing Rab5 effector protein rabenosyn-5, FYVE-finger-containing Rab5 effector protein rabenosyn-5, MGC126210, Rabenosyn-5, ZFYVE20, Zinc finger FYVE domain-containing protein 20, zinc finger, FYVE domain containing 20
Gene Symbol
RBSN
Additional Rabenosyn 5 Products
Product Specific Notices for Rabenosyn 5 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...